Wink Felipe Vitiello, Schwartsmann Carlos Roberto
Resident Physician in the Orthopedics and Traumatology Service, Santa Casa Hospital Complex, Porto Alegre, RS, Brazil.
Titular Professor of the Discipline of Orthopedics and Traumatology, Foundation of the Federal School of Medical Sciences of Porto Alegre; Head of the Orthopedics and Traumatology Service, Santa Casa Hospital Complex, Porto Alegre, RS, Brazil.
Rev Bras Ortop. 2015 Nov 16;45(2):148-50. doi: 10.1016/S2255-4971(15)30284-6. eCollection 2010 Mar-Apr.
To evaluate hepatic changes resulting from the use of enoxaparin for prophylaxis of deep vein thrombosis among patients undergoing total hip arthroplasty.
Thirty-two patients underwent elective total hip arthroplasty, using enoxaparin, and were followed up for 65 days with serial hepatic enzyme assays.
Changes in laboratory parameters were found in up to 75% of the patients during the study, but the parameters normalized after suspension of the treatment. No clinical evidence of hepatic lesions was found.
The hepatic enzyme levels increase in most patients using enoxaparin, but without clinical correlation, and the levels normalize after suspension of the treatment.
评估在接受全髋关节置换术的患者中使用依诺肝素预防深静脉血栓形成所导致的肝脏变化。
32例患者接受了使用依诺肝素的择期全髋关节置换术，并通过连续的肝酶检测进行了65天的随访。
在研究期间，高达75%的患者出现了实验室参数变化，但在治疗暂停后参数恢复正常。未发现肝脏病变的临床证据。
大多数使用依诺肝素的患者肝酶水平升高，但与临床无关，且在治疗暂停后水平恢复正常。
